The weight-loss drug Zepbound is about to be substantially much less expensive for the select group of people who take the medication.It’s even simpler than its rival, semaglutide, marketed as copyright for type two diabetes and Wegovy for weight management. The efficacy of those medicines has created them hugely popular, contributing to shortage